Published in Medical Letter on the CDC and FDA, May 24th, 2006
The trial design changes include:
- Sample size reduction, from 390 to 208 patients. This reduction in patient enrollment is expected to significantly reduce the time required to complete the trial. The RELIANT Destination Therapy trial has already enrolled nearly 20% of the newly required number. The rate of patient...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.